Hung Yi-Chieh, Lee Cheng-Chia, Liu Kang-Du, Chung Wen-Yuh, Pan David Hung-Chi, Yang Huai-Che
Division of Neurosurgery, Department of Surgery, Chi-Mei Foundation Hospital, Tainan;
J Neurosurg. 2014 Dec;121 Suppl:203-9. doi: 10.3171/2014.7.GKS141432.
The authors evaluated individual anatomical variations in the trigeminal nerves of patients with medically intractable trigeminal neuralgia and clarified the relationships among the variations, radiosurgical target locations, and the clinical outcomes after high-dose Gamma Knife surgery (GKS).
From 2006 through 2011, the authors conducted a retrospective review of 106 cases of primary or secondary trigeminal neuralgia consecutively treated with GKS targeting the dorsal root entry zone (DREZ) for which a maximal dose of 90 Gy and a 20% isodose line to the brainstem were used. A questionnaire was used to evaluate patients' pre- and post-GKS clinical conditions. To evaluate individual anatomical variations among trigeminal nerves, the authors used 3 parameters: the length of the trigeminal nerve in the cistern (nerve length), the length of the target between the radiation shot and the brainstem (targeting length), and the ratio between nerve length and targeting length (targeting ratio).
The median length of the trigeminal nerves in the 106 patients was 9.6 mm (range 6.04-20.74 mm), the median targeting length was 3.8 mm (range 1.81-10.84 mm), and the median targeting ratio was 38% (range 13%- 80%). No statistically significant differences in pain relief and pain recurrence were detected among patients with these various nerve characteristics. However, radiation-induced facial hypesthesia correlated with nerve length and targeting ratio (p < 0.05) but not with absolute distance from the brainstem (targeting length).
In trigeminal neuralgia patients who received DREZ-targeted GKS, the rate of pain relief did not differ according to anatomical nerve variations. However, the frequency of facial hypesthesia was higher among patients in whom the nerve was longer (> 11 mm) or the targeting ratio was lower (< 36%). Adjusting the target according to the targeting ratio, especially for patients with longer nerves, can reduce facial hypesthesia and enable maintenance of effective pain control.
作者评估了药物治疗无效的三叉神经痛患者三叉神经的个体解剖变异,并阐明了这些变异、放射外科靶点位置与高剂量伽玛刀手术(GKS)后临床结果之间的关系。
2006年至2011年,作者对106例原发性或继发性三叉神经痛患者进行了回顾性研究,这些患者均接受了以背根入髓区(DREZ)为靶点的GKS治疗,最大剂量为90 Gy,脑干的等剂量线为20%。采用问卷调查评估患者GKS治疗前后的临床状况。为评估三叉神经之间的个体解剖变异,作者使用了3个参数:脑池内三叉神经的长度(神经长度)、放射照射点与脑干之间靶点的长度(靶点长度)以及神经长度与靶点长度的比值(靶点比值)。
106例患者三叉神经的中位长度为9.6 mm(范围6.04 - 20.74 mm),中位靶点长度为3.8 mm(范围1.81 - 10.84 mm),中位靶点比值为38%(范围13% - 80%)。在具有这些不同神经特征的患者中,未检测到疼痛缓解和疼痛复发方面的统计学显著差异。然而,放射性面部感觉减退与神经长度和靶点比值相关(p < 0.05),但与距脑干的绝对距离(靶点长度)无关。
在接受以DREZ为靶点的GKS治疗的三叉神经痛患者中,疼痛缓解率不因解剖神经变异而有所不同。然而,在神经较长(> 11 mm)或靶点比值较低(< 36%)的患者中,面部感觉减退的发生率较高。根据靶点比值调整靶点,尤其是对于神经较长的患者,可以减少面部感觉减退并维持有效的疼痛控制。